Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial
Jupiter Neurosciences (NASDAQ: JUNS) has announced a strategic partnership with Zina Biopharmaceuticals to advance its Phase 2a clinical trial for Parkinson's disease. The trial will evaluate JOTROL™, Jupiter's patented resveratrol-based therapeutic platform, focusing on safety, tolerability, and pharmacokinetics/pharmacodynamics in Parkinson's patients.
JOTROL's micellar formulation addresses historical resveratrol limitations by enhancing bioavailability while reducing gastrointestinal side effects. Preclinical studies have shown promise in reducing neurodegeneration biomarkers. Under the agreement, Zina will provide comprehensive services including protocol design, regulatory strategy, and trial site selection.
The partnership aims to accelerate development for the Parkinson's market, which affects over 10 million people globally and is projected to exceed $14 billion by 2030. Jupiter is also exploring additional partnerships to expand JOTROL's applications in other neuroinflammatory and metabolic disorders.
Jupiter Neurosciences (NASDAQ: JUNS) ha annunciato una partnership strategica con Zina Biopharmaceuticals per portare avanti il suo trial clinico di fase 2a per il morbo di Parkinson. Lo studio valuterà JOTROL™, la piattaforma terapeutica brevettata a base di resveratrolo di Jupiter, concentrandosi su sicurezza, tollerabilità e farmacocinetica/farmacodinamica nei pazienti con Parkinson.
La formulazione micellare di JOTROL affronta le limitazioni storiche del resveratrolo migliorando la biodisponibilità e riducendo gli effetti collaterali gastrointestinali. Gli studi preclinici hanno mostrato risultati promettenti nella riduzione dei biomarcatori di neurodegenerazione. Sotto l'accordo, Zina fornirà servizi completi, tra cui progettazione del protocollo, strategia regolatoria e selezione dei siti di sperimentazione.
La partnership mira ad accelerare lo sviluppo per il mercato del Parkinson, che colpisce oltre 10 milioni di persone a livello globale e si prevede supererà i 14 miliardi di dollari entro il 2030. Jupiter sta anche esplorando ulteriori partnership per espandere le applicazioni di JOTROL in altri disturbi neuroinfiammettori e metabolici.
Jupiter Neurosciences (NASDAQ: JUNS) ha anunciado una asociación estratégica con Zina Biopharmaceuticals para avanzar en su ensayo clínico de fase 2a para la enfermedad de Parkinson. El ensayo evaluará JOTROL™, la plataforma terapéutica patentada a base de resveratrol de Jupiter, centrándose en la seguridad, la tolerabilidad y la farmacocinética/farmacodinámica en pacientes con Parkinson.
La formulación micelar de JOTROL aborda las limitaciones históricas del resveratrol al mejorar la biodisponibilidad y reducir los efectos secundarios gastrointestinales. Los estudios preclínicos han mostrado resultados prometedores en la reducción de biomarcadores de neurodegeneración. Según el acuerdo, Zina proporcionará servicios integrales, incluyendo diseño de protocolo, estrategia regulatoria y selección de sitios de ensayo.
La asociación tiene como objetivo acelerar el desarrollo para el mercado del Parkinson, que afecta a más de 10 millones de personas en todo el mundo y se proyecta que superará los 14 mil millones de dólares para 2030. Jupiter también está explorando asociaciones adicionales para expandir las aplicaciones de JOTROL en otros trastornos neuroinflamatorios y metabólicos.
주피터 네우로사이언스(NASDAQ: JUNS)는 지나 바이오제약과 파킨슨병을 위한 2a 단계 임상 시험을 진행하기 위해 전략적 파트너십을 체결했다고 발표했습니다. 이 시험은 주피터의 특허 받은 레스베라트롤 기반 치료 플랫폼인 JOTROL™의 안전성, 내약성, 약리학적 동태와 약리학적 효과를 파킨슨 환자에게 평가할 것입니다.
JOTROL의 미셀 형성은 레스베라트롤의 역사적인 한계를 해결하여 생체 이용률을 향상시키고 위장 부작용을 줄입니다. 전임상 연구에서는 신경퇴행 바이오마커를 줄이는 데 유망한 결과를 보여주었습니다. 협정에 따라 지나가 프로토콜 설계, 규제 전략 및 시험 장소 선택을 포함한 포괄적인 서비스를 제공할 것입니다.
이 파트너십의 목표는 1천만 명 이상의 환자를 보유하고 있으며 2030년까지 140억 달러를 초과할 것으로 예상되는 파킨슨 시장의 개발을 가속화하는 것입니다. 주피터는 또한 다른 신경 염증 및 대사 장애에서 JOTROL의 적용을 확장하기 위해 추가 파트너십을 탐색하고 있습니다.
Jupiter Neurosciences (NASDAQ: JUNS) a annoncé un partenariat stratégique avec Zina Biopharmaceuticals pour faire progresser son essai clinique de phase 2a sur la maladie de Parkinson. L'essai évaluera JOTROL™, la plateforme thérapeutique brevetée à base de resvératrol de Jupiter, en mettant l'accent sur la sécurité, la tolérance et la pharmacocinétique/pharmacodynamique chez les patients parkinsoniens.
La formulation micellaire de JOTROL répond aux limitations historiques du resvératrol en améliorant la biodisponibilité tout en réduisant les effets secondaires gastro-intestinaux. Les études précliniques ont montré des résultats prometteurs dans la réduction des biomarqueurs de neurodégénérescence. En vertu de l'accord, Zina fournira des services complets, y compris la conception de protocoles, la stratégie réglementaire et la sélection des sites d'essai.
Le partenariat vise à accélérer le développement pour le marché de Parkinson, qui touche plus de 10 millions de personnes dans le monde et devrait dépasser 14 milliards de dollars d'ici 2030. Jupiter explore également d'autres partenariats pour élargir les applications de JOTROL dans d'autres troubles neuroinflammatoires et métaboliques.
Jupiter Neurosciences (NASDAQ: JUNS) hat eine strategische Partnerschaft mit Zina Biopharmaceuticals angekündigt, um die klinische Studie der Phase 2a zur Parkinson-Krankheit voranzutreiben. Die Studie wird JOTROL™, die patentierte, auf Resveratrol basierende therapeutische Plattform von Jupiter, hinsichtlich Sicherheit, Verträglichkeit und Pharmakokinetik/Pharmakodynamik bei Parkinson-Patienten bewerten.
Die micellare Formulierung von JOTROL behebt historische Resveratrol-Einschränkungen, indem sie die Bioverfügbarkeit erhöht und gastrointestinale Nebenwirkungen reduziert. Vorklinische Studien haben vielversprechende Ergebnisse zur Reduzierung von Biomarkern der Neurodegeneration gezeigt. Im Rahmen der Vereinbarung wird Zina umfassende Dienstleistungen anbieten, einschließlich Protokollgestaltung, regulatorischer Strategie und Auswahl der Prüfstellen.
Die Partnerschaft zielt darauf ab, die Entwicklung für den Parkinsonmarkt zu beschleunigen, der weltweit über 10 Millionen Menschen betrifft und voraussichtlich bis 2030 über 14 Milliarden Dollar überschreiten wird. Jupiter erkundet auch zusätzliche Partnerschaften, um die Anwendungen von JOTROL in anderen neuroinflammatorischen und metabolischen Erkrankungen auszubauen.
- Advancing to Phase 2a clinical trials for Parkinson's disease
- Strategic partnership secured for comprehensive trial support
- Preclinical studies show positive results in neurodegeneration biomarkers
- Targeting large market opportunity ($14B by 2030)
- Enhanced drug bioavailability with reduced side effects
- Early-stage clinical development with no proven efficacy yet
- Operating in highly competitive market with established players
- No current revenue generation from product
Insights
The strategic partnership between Jupiter Neurosciences and Zina Biopharmaceuticals marks a important advancement in JOTROL's clinical development program. The collaboration addresses several critical aspects that could significantly impact the company's trajectory:
Technical Innovation: JOTROL's micellar formulation represents a significant breakthrough in resveratrol delivery. Traditional resveratrol treatments have been by poor bioavailability and gastrointestinal side effects. The enhanced bioavailability achieved through JOTROL's formulation could potentially translate to improved therapeutic outcomes, particularly important in CNS disorders where drug delivery is challenging.
Trial Design Strategy: The Phase 2a trial's dual focus on safety/tolerability and PK/PD endpoints is strategically sound. This approach will not only establish the basic safety profile but also provide important data on drug behavior and biological effects, essential for optimizing dosing in future pivotal studies. The inclusion of biomarker analysis aligns with modern drug development practices and could provide early signals of efficacy.
Market Positioning: With the Parkinson's therapeutics market projected to exceed
Development Risk Assessment: While promising, several challenges warrant attention: 1) The historical difficulty in developing CNS therapeutics 2) The complexity of conducting Parkinson's trials with appropriate endpoints 3) The need for substantial funding to support multiple clinical programs 4) The competitive landscape of Parkinson's drug development.
The strategic partnership with Zina Biopharmaceuticals could significantly enhance Jupiter's operational efficiency and financial position. Key financial implications include:
Resource Optimization: By leveraging Zina's expertise and infrastructure, Jupiter can potentially reduce the operational costs typically associated with trial execution. This arrangement allows for more efficient resource allocation and potentially lower burn rate during the critical Phase 2a stage.
Market Opportunity Analysis: The
Development Strategy: The company's approach of seeking additional strategic partnerships for expanding JOTROL's applications demonstrates a thoughtful strategy to maximize the platform's commercial potential while managing development risks and costs. This could lead to multiple revenue streams and reduced dependency on a single indication.
Financial Considerations: With a market cap of
Jupiter, Florida, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced a strategic partnership with Zina Biopharmaceuticals, LLC ("Zina") to support all aspects of Jupiter’s upcoming Phase 2a clinical trial for Parkinson’s disease.
Under the terms of the agreement, Zina will provide comprehensive services related to the execution of the exploratory Phase 2a trial evaluating JOTROL™, Jupiter’s patented resveratrol-based therapeutic platform. The primary objective of the trial will be to evaluate the safety and tolerability of JOTROL in patients with Parkinson’s, with secondary and exploratory endpoints to assess pharmacokinetics/pharmacodynamics (PK/PD) of the drug.
JOTROL’s innovative micellar formulation overcomes the historical limitations of resveratrol by achieving significantly enhanced bioavailability while minimizing gastrointestinal side effects. Preclinical studies have demonstrated JOTROL’s potential in mitigating key biomarkers associated with neurodegeneration, supporting its potential application in Parkinson’s disease and other central nervous system (CNS) disorders.
“This partnership with Zina marks a significant milestone for Jupiter as we advance JOTROL into Phase 2 clinical development for Parkinson’s,” said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. “Zina’s extensive expertise in trial execution, as well as regulatory, clinical and scientific strategy, will be instrumental in accelerating our development timeline and positioning us for future pivotal studies.”
Under the agreement, Zina will assist with clinical trial protocol design, including pharmacokinetics and biomarkers, regulatory strategy, and trial site selection to facilitate a smooth trial execution and future clinical progression.
Parkinson’s disease affects over 10 million people worldwide, with no disease-modifying treatments currently available. The global Parkinson’s therapeutics market is projected to exceed
Jupiter is actively exploring additional strategic partnerships to expand JOTROL’s application across other neuroinflammatory and metabolic disorders, including Alzheimer’s disease and longevity medicine.
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on treating neuroinflammation, with a current focus on CNS disorders and rare diseases. The Company’s platform product, JOTROL™, is an enhanced orally administered resveratrol formulation designed and intended to deliver therapeutically relevant, safe levels of resveratrol. The Company’s pipeline is focused broadly on CNS disorder and includes indications such as Alzheimer’s Disease, Parkinson’s Disease, Mucopolysaccharidoses Type I, Friedreich’s Ataxia, and MELAS. More information may be found on the Company’s website www.jupiterneurosciences.com.
About JOTROL
Resveratrol is one of the world’s most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication.
Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer’s Disease trial, and Yui et al., Friedreich’s Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL trials, were published in the Journal of Alzheimer’s Disease and AAPS Open in February 2022.
About Zina Biopharmaceuticals, LLC
Zina Biopharmaceuticals is a specialized consulting company providing end-to-end trial design and execution solutions as well as regulatory, scientific and medical advice for biotech and pharmaceutical companies.
FORWARD-LOOKING STATEMENTS
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations, including the use of proceeds from the Offering. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company’s final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company’s securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.
Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
1-800-RED-CHIP (733-2447)
JUNS@redchip.com
FAQ
What are the main objectives of JUNS Phase 2a Parkinson's trial?
How does JOTROL's formulation improve upon traditional resveratrol treatments?
What is the market potential for JUNS's Parkinson's treatment?
What role will Zina Biopharmaceuticals play in JUNS's Phase 2a trial?
What other therapeutic areas is JUNS exploring for JOTROL?
